A business in context

ACHV research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-22 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-05 · 0001953943-26-000004

  2. 8-K · Current report

    Report date 2026-10-01 · 0001193125-26-410781 · Items 5.02

  3. 4 · Ownership change

    Report date 2026-08-19 · 0001193125-26-361182

  4. 8-K · Current report

    Report date 2026-08-14 · 0001193125-26-352229 · Items 8.01,9.01

  5. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-344624

  6. 8-K · Current report

    Report date 2026-08-11 · 0001193125-26-344571 · Items 2.02,9.01

  7. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324262

  8. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324256

  9. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324253

  10. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324250

  11. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324245

  12. 4 · Ownership change

    Report date 2026-07-27 · 0001193125-26-324238

  13. 8-K · Current report

    Report date 2026-07-02 · 0001193125-26-296174 · Items 5.03,5.07,9.01

  14. DEF 14A · Proxy statement

    Report date 2026-06-08 · 0000949858-26-000006

  15. 8-K · Current report

    Report date 2026-05-29 · 0001193125-26-252624 · Items 5.02

  16. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-218177

  17. 8-K · Current report

    Report date 2026-05-07 · 0001193125-26-218175 · Items 2.02,5.02,9.01

  18. 10-K/A · Annual report

    Report date 2025-12-31 · 0001193125-26-197402

  19. 8-K · Current report

    Report date 2026-04-15 · 0001193125-26-159189 · Items 1.01,3.02,5.02,7.01,9.01

  20. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-120690

  21. 8-K · Current report

    Report date 2026-03-24 · 0001193125-26-120687 · Items 2.02,9.01

  22. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-268074

  23. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-268056 · Items 2.02,9.01

  24. 8-K · Current report

    Report date 2025-10-06 · 0001193125-25-233581 · Items 5.02

  25. 8-K · Current report

    Report date 2025-09-05 · 0001193125-25-201418 · Items 5.02

  26. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-104571

  27. 8-K · Current report

    Report date 2025-08-07 · 0000950170-25-104569 · Items 2.02,9.01

  28. 8-K · Current report

    Report date 2025-06-26 · 0000950170-25-091055 · Items 1.01,8.01,9.01

  29. 8-K · Current report

    Report date 2025-06-04 · 0000950170-25-083214 · Items 5.07

  30. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-069806

  31. 8-K · Current report

    Report date 2025-05-13 · 0000950170-25-069804 · Items 2.02,9.01

  32. DEF 14A · Proxy statement

    Report date 2025-04-28 · 0000950170-25-059297

  33. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-036831

  34. 8-K · Current report

    Report date 2025-03-11 · 0000950170-25-036830 · Items 2.02,9.01

  35. 8-K · Current report

    Report date 2025-02-10 · 0000950170-25-017068 · Items 8.01,9.01

  36. 8-K · Current report

    Report date 2025-01-06 · 0000950170-25-003873 · Items 5.02

  37. 8-K · Current report

    Report date 2024-12-05 · 0000950170-24-134558 · Items 5.02

  38. SC 13G/A · Ownership disclosure

    0000932471-24-000823

  39. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-123375

  40. 8-K · Current report

    Report date 2024-11-07 · 0000950170-24-123334 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 14 transaction rows14AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

15 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-19
2026-08-21
Stewart Richard AlistairS · Sale
Disposed
Common Stock20626.08.49
2026-07-27
2026-07-29
Sellig ThomasA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Sellig ThomasA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Martin Christopher NathanA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Martin Christopher NathanA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Royston AaronA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Royston AaronA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Waldman Reid AlexanderA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Waldman Reid AlexanderA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Stewart Richard AlistairA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Stewart Richard AlistairA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Farrow Jeffrey SA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0
2026-07-27
2026-07-29
Farrow Jeffrey SA · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Phelan Nancy R.A · Grant / award
Acquired
Restricted Stock Unit (RSU)
Derivative security
16700.00.0
2026-07-27
2026-07-29
Phelan Nancy R.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
25000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000949858ACHIEVE LIFE SCIENCES, INC.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • ONCOGENEX PHARMACEUTICALS, INC. · former SEC name · 2008-08-21 to 2017-07-31
  • SONUS PHARMACEUTICALS INC · former SEC name · 1996-05-24 to 2008-08-07

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2019-12-31$0$0
2018-12-31$0$0

Bureau of Labor Statistics · retrieved 2026-10-22 · 9 selected series; gaps remain missing

Explore the CPI history ↗